TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.62
−2.95%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$3.73
From 52W high−48.14%
Volume2.72M
Market cap$1.18B
P/E (TTM)—
P/S (TTM)215.0x
Div yield—
Key dataOct 16, 2026
Open
$3.73
From 52W high
−48.14%
Volume
2.72M
Market cap
$1.18B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
P/E (TTM)
—
RSI (14)
25.8
MomentumView details →
1D Return
−2.95%
YTD Return
−34.20%
SummaryUpdated Jun 1, 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company founded in 2019 and based in Dallas, Texas. The company went public in September 2020 and focuses on developing gene therapies for rare monogenic diseases affecting the central nervous system. Taysha has established a strategic partnership with The University of Texas Southwestern Medical Center to advance transformative gene therapy treatments. The company is currently advancing its lead program TSHA-102 through Phase 1/2 clinical trials for Rett syndrome, having completed dosing of 10 patients with encouraging preliminary results.
Similar companies
Latest newsMore news →
The Phoenix Art Museum received a $5m gift from philanthropist Sukumar Nagendran to expand its Art of Asia galleries from about 6,000 sq. ft to 10,000 sq. ft and create a new 2,000-sq.-ft Nagendran Gallery for the Art of Sri Lanka and South Asia.11d agoTaysha Gene Therapies, Inc. held its Q2 2026 earnings call on August 11, 2026.66d ago